Revance Therapeutics Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	526.3	2,504	276.3	-0.3
Depreciation & Amortization	169.7	162	216.3	-
Other Amortization	-	-	0.7	-
Gain (Loss) on Sale of Assets	-360.7	-2,981	70.1	-
Gain (Loss) on Sale of Investments	-131	-51.3	-0.7	-
Change in Accounts Receivable	146.1	150.4	11.3	-
Change in Accounts Payable	97.2	180.7	120.1	0.3
Change in Other Net Operating Assets	374.9	148.4	-572.6	-
Other Operating Activities	42.5	689.1	279	-
Net Cash from Discontinued Operations	-	62.5	769.7	-
Operating Cash Flow	851.7	751.4	1,184	-
Operating Cash Flow Growth	13.35%	-36.55%	-	-
Acquisition of Real Estate Assets	-1,809	-2,576	-855.1	-
Sale of Real Estate Assets	689.2	14.1	105	-
Net Sale / Acq. of Real Estate Assets	-1,120	-2,562	-750.1	-
Cash Acquisition	-117.4	-	-	-
Investment in Marketable & Equity Securities	1,288	-4,050	834.9	-
Other Investing Activities	0.2	1,198	22.8	-
Investing Cash Flow	283.5	-263.4	-779.7	-
Long-Term Debt Issued	-	-	1,116	-
Short-Term Debt Repaid	-206.2	-395.8	-	-
Long-Term Debt Repaid	-388.7	-98.6	-916	-
Total Debt Repaid	-594.9	-494.4	-916	-
Net Debt Issued (Repaid)	-594.9	-494.4	199.6	-
Common Dividends Paid	-122.8	-	-	-
Other Financing Activities	-67.4	-66.6	-580.7	-
Miscellaneous Cash Flow Adjustments	0.4	-	141.3	-
Net Cash Flow	350.5	-73	164.8	-
Cash Interest Paid	23.2	-	3.1	-
Cash Income Tax Paid	189	222.1	102.6	-
Levered Free Cash Flow	-889.45	4,658	-	-
Unlevered Free Cash Flow	-868.39	4,709	-	-
Change in Working Capital	618.4	484.6	-441.2	0.3

Updated Jan 30, 2025. Source: S&P Global Market Intelligence. Real Estate template. Financial Sources.